ScripEli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i
ScripInsmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its s
In VivoThe 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th
ScripThe 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th